MedPath

Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

Phase 3
Terminated
Conditions
Lymphoma
Registration Number
NCT00004874
Lead Sponsor
University of Nebraska
Brief Summary

RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.

PURPOSE: Phase III trial to determine the effectiveness of monoclonal antibody therapy in treating patients who have relapsed or refractory non-Hodgkin's lymphoma.

Detailed Description

OBJECTIVES: I. Determine the efficacy and safety of iodine I 131 monoclonal antibody anti-B1 in patients with relapsed or refractory, low grade or transformed low grade B-cell non-Hodgkin's lymphoma.

OUTLINE: On day 1, patients receive unlabeled monoclonal antibody anti-B1 (MOAB anti-B1) IV over 1 hour followed by a tracer dose of iodine I 131 MOAB anti-B1 IV over 30 minutes to determine biodistribution and a therapeutic dose of iodine I 131 MOAB anti-B1. Patients receive unlabeled MOAB anti-B1 IV over 1 hour followed by a therapeutic dose of iodine I 131 MOAB anti-B1 IV over 30 minutes on day 8. Patients are followed at weeks 13 and 25 and then every 6 months for up to 2 years.

PROJECTED ACCRUAL: Expanded Access Trial, no maximum accrual

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
31
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Expanded AccessStudy completion

The primary objective of this stud is to make Iodin-131 Anti-B1 Antibody more broadly available to patients

Secondary Outcome Measures
NameTimeMethod
efficacystudy completion

Secondary endpoints of the study will be to obtain additional information on the efficacy of Iodine-131 Anti-B1 Antibody

SafetyStudy completion

Secondary endpoints of the study will be to obtain additional information on the safety of Iodine-131 Anti-B1 Antibody

Trial Locations

Locations (1)

University of Nebraska Medical Center

🇺🇸

Omaha, Nebraska, United States

University of Nebraska Medical Center
🇺🇸Omaha, Nebraska, United States
© Copyright 2025. All Rights Reserved by MedPath